Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

LEO FARMACEUTICOS

NIF 503932680
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €421,506 17 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €421,506 17 contracts
A2 · Late Publication €3,203,710,825 613 contracts
Contract published to BASE more than 10 days after the signing date
LOW €3,203,710,825 613 contracts
A5 · Threshold Splitting €6,581,625 17 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €6,581,625 17 contracts
A6 · Low Competition €98,165 5 contracts
Only one bidder participated in a competitive procedure
MEDIUM €98,165 5 contracts
A9 · Abnormal Price Reduction €4,092,941,234 484 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €4,092,941,234 484 contracts
C3 · Missing Mandatory Fields €2,197,792 37 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €2,197,792 37 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

69
€217,666,541
39
€190,417,890
18
€183,062,991
28
€179,701,655
20
€177,638,380
22
€177,193,023
11
€175,735,211
11
€175,300,567
7
€167,511,735
29
€166,553,686
7
€164,200,291
28
€161,868,222
14
€161,011,486
5
€160,721,157
23
€160,607,034
5
€159,726,542
25
€157,281,816
19
€153,765,042
14
€152,251,899
21
€152,014,502
Page 1 of 3 · 60 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 5 contracts

Fornecimento de substância ativa: Tralocinumab 150 mg/1 ml
PT · 11281535 · Ajuste Direto Regime G...
A6 · Low Competition
€18,403 2025-03-12
Aquisição de TRALOCINUMAB 150 MG/1 ML SOL INJ SER 1 ML SC
PT · 11218196 · Contratação excluída II
A2 · Late Publication A6 · Low Competition
€29,944 2025-01-28
HEPARINA SODICA
PT · 11026838 · Ao abrigo de acordo-qu...
A6 · Low Competition
€16,131 2024-11-15
J1/2621/2024 – TRALOCINUMAB 150 MG / ML SOL INJ SER 1 ML SC
PT · 10928990 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€17,467 2024-08-21
AQUISIÇÃO DE MEDICAMENTOS LEO - AUE - 2024
PT · 10647762 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€16,220 2024-01-03
Overview
Total Value Won
€4,108,159,733
Contracts Won
843
Score 31645 · CRITICAL RISK
NIF
503932680
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.J. [P-3c29]
    Gerente
    since 2024-01-24
  • A.J. [P-3c29]
    Gerente
    since 2026-02-23
  • A.K. [P-7b78]
    Gerente
    since 2016-05-16
  • A.K. [P-7b78]
    Gerente
    since 2017-11-16
  • A.K. [P-7b78]
    Gerente
    since 2020-03-12
  • D.A. [P-c2b1]
    Gerente
    since 2020-03-12
  • D.A. [P-c2b1]
    Gerente
    since 2022-11-07
  • D.A. [P-c2b1]
    Gerente
    since 2026-02-23
  • G.P. [P-734c]
    Gerente
    since 2010-05-31
  • G.P. [P-734c]
    Gerente
    since 2014-10-10
  • G.P. [P-734c]
    Gerente
    since 2016-05-16
  • G.P. [P-734c]
    Gerente
    since 2017-11-16
  • J.H. [P-17da]
    Gerente
    since 2022-11-07
  • J.C. [P-75e0]
    Gerente
    since 2020-03-12
  • J.C. [P-75e0]
    Gerente
    since 2022-11-07
  • J.C. [P-75e0]
    Gerente
    since 2026-02-23
  • L.E. [P-a363]
    Gerente
    since 2012-07-03
  • L.E. [P-a363]
    Gerente
    since 2014-10-10
  • L.O. [P-02c7]
    Gerente
    since 2010-05-31
  • L.O. [P-02c7]
    Gerente
    since 2014-10-10
  • M.S. [P-22c9]
    Gerente
    since 2020-12-04
  • N.M. [P-9597]
    Gerente
    since 2011-09-05
  • N.M. [P-9597]
    Gerente
    since 2014-10-10
  • N.M. [P-9597]
    Gerente
    since 2020-12-04
  • N.M. [P-9597]
    Gerente
    since 2022-11-07
  • P.C. [P-aa9c]
    Gerente
    since 2017-11-16
  • V.L. [P-53ed]
    Gerente
    since 2025-11-21
  • V.L. [P-53ed]
    Gerente
    since 2026-02-23
  • G.P. [P-1ac3]
    Gerente
    2020-03-12 → 2020-12-04
  • J.F. [P-685f]
    Gerente
    2024-04-26 → 2025-11-21
  • J.P. [P-3c19]
    Gerente
    2010-05-31 → 2012-07-03
  • J.B. [P-90de]
    Gerente
    until 2010-05-31
  • M.A. [P-5a44]
    Gerente
    2010-05-31 → 2011-09-02
  • N.M. [P-9597]
    Gerente
    2016-05-16 → 2017-11-16
  • P.C. [P-aa9c]
    Gerente
    2020-03-12 → 2020-12-04
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned